Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||05/08/2020|
|Rapid review completed||28/09/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of encorafenib plus cetuximab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||30/09/2020|
|Pre-submission consultation with Applicant||15/03/2021|
|Full HTA submission received from Applicant||29/06/2021|
|Preliminary review sent to Applicant||17/09/2021|
|NCPE assessment re-commenced||05/11/2021|
|Factual accuracy sent to Applicant||23/12/2021|
|NCPE assessment re-commenced||10/01/2022|
|NCPE assessment completed||28/01/2022|
|NCPE assessment outcome||The NCPE recommends that encorafenib, in combination with cetuximab, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.